Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial
1 Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Electronic address: spal@coh.org.
2 Division of Hematology/Oncology, Department of Medicine, University of Washington, Seattle, WA, USA; Fred Hutchinson Cancer Center, Seattle, WA, USA.
3 Department of Hematologic and Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
4 Department of Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
5 Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.
6 Hospital Universitario Virgen del Rocio, Sevilla, Spain.
7 Hospital del Mar, CIBERONC, IMIM Research Institute, Barcelona, Spain.
8 Marien Hospital Herne, Herne, Germany.
9 Hospital Universitario HM Sanchinarro-Centro Integral Oncologico Clara Campal, Madrid, Spain.
10 Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
11 Department of Medicine, Gustave Roussy, Villejuif, France.
12 Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.
13 Department of Genitourinary Oncology, AdventHealth Cancer Institute, Orlando, FL, USA.
14 Department of Medical Oncology, Virginia Oncology Associates, Norfolk, VA, USA.
15 Department of Urology, Baylor College of Medicine, Houston, TX, USA.
16 Dana Farber Cancer Institute, Boston, MA, USA.
17 Department of Urology, Emory University, Atlanta, GA, USA.
18 BridgeBio Inc, Palo Alto, CA, USA.
19 Department of Urology, University of Southern California, Los Angeles, CA, USA.